Clinical spectrum of POLR3-related leukodystrophy caused by biallelic
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
23
04
2019
accepted:
18
09
2019
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
12
2
2020
Statut:
epublish
Résumé
To determine the clinical, radiologic, and molecular characteristics of RNA polymerase III-related leukodystrophy (POLR3-HLD) caused by biallelic A cross-sectional observational study involving 25 centers worldwide was conducted. Clinical and molecular information was collected on 23 unreported and previously reported patients with POLR3-HLD and biallelic pathogenic variants in Fourteen female and 9 male patients aged 7 days to 23 years were included in the study. Most participants presented early in life (birth to 6 years), and motor deterioration was seen during childhood. A notable proportion of patients required a wheelchair before adolescence, suggesting a more severe phenotype than previously described in POLR3-HLD. Dental, ocular, and endocrine features were not invariably present (70%, 50%, and 50%, respectively). Five patients (22%) had a combination of hypomyelinating leukodystrophy and abnormal craniofacial development, including 1 individual with clear Treacher Collins syndrome (TCS) features. Brain MRI revealed hypomyelination in all cases, often with areas of pronounced T2 hyperintensity corresponding to T1 hypointensity of the white matter. Twenty-nine different pathogenic variants (including 12 new disease-causing variants) in This study provides a comprehensive description of POLR3-HLD caused by biallelic
Identifiants
pubmed: 32042905
doi: 10.1212/NXG.0000000000000369
pii: NG2019010652
pmc: PMC6927361
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e369Informations de copyright
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Am J Hum Genet. 2011 Nov 11;89(5):652-5
pubmed: 22036172
Arch Neurol. 2012 Jul;69(7):920-3
pubmed: 22451160
Eur J Pediatr. 2012 Nov;171(11):1611-8
pubmed: 22729243
Neurology. 2016 Apr 26;86(17):1622-6
pubmed: 27029625
Genome Med. 2017 Mar 21;9(1):26
pubmed: 28327206
Brain. 2010 Oct;133(10):2971-82
pubmed: 20881161
Eur J Hum Genet. 2004 Nov;12(11):879-90
pubmed: 15340364
Neurology. 2014 Nov 18;83(21):1898-905
pubmed: 25339210
J Child Neurol. 2014 Feb;29(2):214-20
pubmed: 24105487
Mol Genet Metab. 2015 Apr;114(4):494-500
pubmed: 25649058
J Med Genet. 2018 Dec;55(12):837-846
pubmed: 30323018
Neuropediatrics. 2018 Apr;49(2):112-117
pubmed: 29179231
Neurol Genet. 2018 Dec 03;4(6):e289
pubmed: 30584594
Nat Commun. 2015 Jul 07;6:7623
pubmed: 26151409
Nature. 2016 Dec 22;540(7634):607-610
pubmed: 27842382
Genet Med. 2016 Jan;18(1):49-56
pubmed: 25790162
Nat Genet. 2011 Jan;43(1):20-2
pubmed: 21131976
Mol Genet Metab. 2015 Apr;114(4):501-515
pubmed: 25655951
J Med Genet. 2013 Mar;50(3):194-7
pubmed: 23355746
Nature. 2013 Oct 31;502(7473):644-9
pubmed: 24153184
Brain. 2017 Jun 1;140(6):1561-1578
pubmed: 28459997
Eur J Hum Genet. 2017 Feb;25(3):315-323
pubmed: 28051070
Clin Neuroradiol. 2017 Jun;27(2):213-220
pubmed: 26478204
Am J Med Genet A. 2019 Jul;179(7):1390-1394
pubmed: 30957429
PLoS One. 2016 Aug 04;11(8):e0160519
pubmed: 27490490
NPJ Genom Med. 2018 Apr 4;3:10
pubmed: 29644095
Mol Cell. 2016 Dec 15;64(6):1135-1143
pubmed: 27867008
Nature. 2013 Oct 31;502(7473):650-5
pubmed: 24153182
PLoS Genet. 2016 Jul 22;12(7):e1006187
pubmed: 27448281
Neuropediatrics. 2016 Dec;47(6):349-354
pubmed: 27564080
Orphanet J Rare Dis. 2015 Jun 05;10:69
pubmed: 26045207
Am J Hum Genet. 2011 Sep 9;89(3):415-23
pubmed: 21855841
Am J Med Genet A. 2013 Mar;161A(3):445-52
pubmed: 23401420
Neurology. 2009 Feb 24;72(8):750-9
pubmed: 19237705
Brain. 2018 Jan 1;141(1):e2
pubmed: 29236946
Mol Biol Evol. 2010 Feb;27(2):221-4
pubmed: 19854763
Brain. 2018 Jan 1;141(1):e1
pubmed: 29228109